Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Armandi

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Nursing Reports (Pavia, Italy)|December 30, 2021
Inflammatory Bowel Disease Nurse-Practical MessagesChiara Rosso, Alami Aroussi Aaron, Angelo Armandi, et al.
Journal of Clinical Medicine|September 9, 2022
Predictive Factors of Surgical Recurrence in Patients with Crohn's Disease on Long-Term Follow-Up: A Focus on HistologyGian Paolo Caviglia, Chiara Angela Mineo, Chiara Rosso, et al.
Inflammatory Bowel Diseases|December 5, 2025
Reply: "Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care"Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa, et al.
Inflammatory Bowel Diseases|September 7, 2025
When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter StudyLorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2018
Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapyEndrit Shahini, Andrea Iannone, Domenico Romagno, et al.
Inflammatory Bowel Diseases|March 14, 2026
Response to Letter to the Editor: "Enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis"Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa, et al.
Clinical Nutrition (Edinburgh, Scotland)|October 3, 2023
A nutrigenetic precision approach for the management of non-alcoholic fatty liver diseaseNuria Perez-Diaz-Del-Campo, Eleonora Dileo, Gabriele Castelnuovo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 28, 2022
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individualsChiara Saponaro, Silvia Sabatini, Melania Gaggini, et al.
Alimentary Pharmacology & Therapeutics|March 11, 2024
Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept studyAngelo Armandi, Helena Bespaljko, Alexander Mang, et al.
Immunology|October 30, 2025
IL10 rs1800896 Genetic Variant Predicts Biochemical Remission in Inflammatory Bowel Disease Patients Undergoing Biologic TherapyMichela Helga Falzone, Davide Giuseppe Ribaldone, Martina Buglione, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Nursing Reports (Pavia, Italy)|December 30, 2021
Inflammatory Bowel Disease Nurse-Practical MessagesChiara Rosso, Alami Aroussi Aaron, Angelo Armandi, et al.
Journal of Clinical Medicine|September 9, 2022
Predictive Factors of Surgical Recurrence in Patients with Crohn's Disease on Long-Term Follow-Up: A Focus on HistologyGian Paolo Caviglia, Chiara Angela Mineo, Chiara Rosso, et al.
Inflammatory Bowel Diseases|December 5, 2025
Reply: "Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care"Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa, et al.
Inflammatory Bowel Diseases|September 7, 2025
When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter StudyLorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2018
Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapyEndrit Shahini, Andrea Iannone, Domenico Romagno, et al.
Inflammatory Bowel Diseases|March 14, 2026
Response to Letter to the Editor: "Enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis"Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa, et al.
Clinical Nutrition (Edinburgh, Scotland)|October 3, 2023
A nutrigenetic precision approach for the management of non-alcoholic fatty liver diseaseNuria Perez-Diaz-Del-Campo, Eleonora Dileo, Gabriele Castelnuovo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 28, 2022
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individualsChiara Saponaro, Silvia Sabatini, Melania Gaggini, et al.
Alimentary Pharmacology & Therapeutics|March 11, 2024
Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept studyAngelo Armandi, Helena Bespaljko, Alexander Mang, et al.
Immunology|October 30, 2025
IL10 rs1800896 Genetic Variant Predicts Biochemical Remission in Inflammatory Bowel Disease Patients Undergoing Biologic TherapyMichela Helga Falzone, Davide Giuseppe Ribaldone, Martina Buglione, et al.
Pageof 13